An IgG4 blood test measures one subclass of immunoglobulin G. It is most often ordered when a clinician suspects IgG4-related disease, a systemic fibroinflammatory condition that can enlarge organs, form tumor-like masses, obstruct ducts or vessels, and gradually cause permanent fibrosis. A serum IgG4 concentration above about 135 mg/dL is commonly used as supportive evidence, but the laboratory’s own reference range and the clinical setting matter. Many people with an elevated result do not have IgG4-related disease, and some patients with biopsy-proven disease have a normal level. The diagnosis therefore rests on a combination of organ pattern, imaging, exclusion of mimics, and—when feasible—tissue pathology. The blood result is best viewed as a clue that can raise or lower suspicion, not as a stand-alone diagnosis or a map of every affected organ.
- High serum IgG4 supports suspicion but is not specific for IgG4-related disease.
- Normal IgG4 does not exclude the disease, especially when only one organ is involved.
- The degree of elevation matters; values several times the upper limit are more informative than borderline results.
- Imaging and biopsy are often needed to distinguish inflammation from cancer, infection, and other immune disorders.
- Organ damage can progress quietly, so symptoms and function tests matter even when CRP is normal.
Table of Contents
- What the IgG4 Blood Test Measures
- What a High IgG4 Result Means
- What a Normal or Low Result Means
- Organ Patterns That Raise Suspicion
- How Clinicians Build the Diagnosis
- Using IgG4 to Monitor Disease
- Next Steps and Urgent Warning Signs
What the IgG4 Blood Test Measures
Immunoglobulin G has four subclasses: IgG1, IgG2, IgG3, and IgG4. IgG4 is normally the least abundant. It has unusual immune properties and often increases after prolonged antigen exposure, including some allergic and immune responses. A routine total IgG test combines all four subclasses, whereas an IgG subclass panel reports each one separately.
The serum IgG4 test is usually performed on a standard blood sample. Fasting is not normally required. Results are commonly reported in milligrams per deciliter (mg/dL) or grams per liter (g/L). One gram per liter equals 100 mg/dL. Reference intervals vary with the laboratory and assay, so the range printed beside the result should be used.
A concentration above 135 mg/dL, or 1.35 g/L, appears in widely used diagnostic frameworks for IgG4-related disease. That threshold is a practical starting point rather than a universal biological dividing line. A result of 138 mg/dL carries a different weight from a result of 1,000 mg/dL, even though both may be labeled high.
The test measures circulating protein. It does not directly measure IgG4-positive plasma cells in tissue, storiform fibrosis, or inflammation around ducts and vessels. Those are pathologic features assessed by biopsy. Serum and tissue findings often correlate, but they are not interchangeable.
IgG4-related disease is also not an allergy test, even though some patients have high IgE, eosinophilia, asthma, or allergic symptoms. A high IgG4 concentration alone does not identify a food, medication, or environmental trigger. Likewise, it is not a conventional autoantibody test and does not point to one specific self-antigen.
What a High IgG4 Result Means
A high result increases suspicion when it appears with a characteristic organ pattern. Its diagnostic value depends on three factors: how far above normal it is, why the test was ordered, and whether an alternative condition explains the elevation.
Borderline elevations are common and nonspecific. In health-system studies, a value above 135 mg/dL has had a positive predictive value of only about one third for IgG4-related disease. That means most positive results in an unselected tested population came from other causes. Specificity improves when the concentration is more than two times the upper limit of normal, and very large elevations can be strongly supportive, but no serum level is completely diagnostic.
Other causes of elevated IgG4 include:
- Allergic disease and chronic airway inflammation
- Parasitic or other persistent infections
- Autoimmune pancreatitis of the IgG4-related type, which is part of the disease spectrum
- Primary sclerosing cholangitis and other hepatobiliary disorders
- Some autoimmune and connective-tissue diseases
- Multicentric Castleman disease
- Sarcoidosis and other granulomatous disorders
- Certain cancers, including pancreatic, biliary, and lymphoid malignancies
- Chronic kidney, liver, or inflammatory conditions
The pattern across the immunoglobulin subclasses may add context. IgG4-related disease can produce polyclonal hypergammaglobulinemia, meaning several antibody classes rise together. Serum protein electrophoresis and immunofixation may be ordered when total protein is high or a monoclonal plasma-cell disorder is possible.
A high result does not reveal which organ is involved. It cannot distinguish pancreas from kidney, salivary gland, aorta, or orbit. It also cannot prove that a mass is benign. Assuming that an elevated IgG4 explains a pancreatic or lung lesion without appropriate imaging and tissue assessment can delay a cancer diagnosis.
Some laboratories report the IgG4-to-total IgG ratio. A higher ratio can support interpretation, especially when total IgG is elevated, but the ratio is not a substitute for pathology. Tissue reports may separately give the proportion of IgG-positive plasma cells that stain for IgG4; that is a histologic ratio, not the same measurement as the serum ratio.
What a Normal or Low Result Means
A normal serum IgG4 concentration reduces support for the diagnosis but does not rule it out. A meaningful minority of patients with confirmed IgG4-related disease have levels within the laboratory range. Normal results are more likely in limited disease affecting one organ, in some retroperitoneal or fibrotic presentations, and after treatment has already begun.
A falsely low value can also occur through the prozone or hook effect. In this analytical problem, an extremely high concentration interferes with the assay and produces a deceptively low reading. Modern laboratories reduce this risk by diluting suspicious samples, but clinicians should contact the laboratory when the clinical picture is compelling and the value seems implausibly low.
Corticosteroids, rituximab, and other immune treatments may lower serum IgG4. A sample obtained after therapy begins may therefore be less useful for initial diagnosis. When possible and safe, baseline blood tests are collected before immunosuppression, but treatment should not be delayed in an organ-threatening emergency solely to obtain an ideal biomarker.
Low IgG4 by itself rarely has the same significance as low total IgG. Because IgG4 forms only a small fraction of total immunoglobulin, an isolated low subclass may be incidental. Recurrent severe infections prompt review of total IgG, IgA, IgM, vaccine responses, and other immune-function measures rather than interpretation of IgG4 alone.
The practical rule is that a normal result cannot outweigh characteristic imaging or biopsy findings. If autoimmune pancreatitis, tubulointerstitial nephritis, orbital disease, or retroperitoneal fibrosis remains likely, the evaluation should continue.
Timing also matters. A patient tested during an untreated, multi-organ inflammatory phase is more likely to show a clear elevation than someone tested after months of therapy or after disease has become predominantly fibrotic. The report should therefore be interpreted against the treatment timeline and prior imaging, not as an isolated snapshot.
Organ Patterns That Raise Suspicion
IgG4-related disease can affect almost any organ, often in combinations that appear unrelated until viewed as one systemic process. The inflammation tends to form painless enlargement, wall thickening, nodules, or fibrotic tissue. Fever and striking CRP elevation are less typical than in many infections, although exceptions occur.
Common patterns include:
- Pancreas: Type 1 autoimmune pancreatitis can cause painless jaundice, pancreatic enlargement, abdominal discomfort, weight loss, or new diabetes.
- Bile ducts: IgG4-related sclerosing cholangitis can obstruct bile flow and resemble primary sclerosing cholangitis or cholangiocarcinoma.
- Salivary and lacrimal glands: Persistent, often painless swelling may involve submandibular glands, parotids, or tear glands.
- Orbit: Inflammation may enlarge lacrimal glands, extraocular muscles, or orbital nerves, causing swelling, double vision, or visual risk.
- Kidneys: Tubulointerstitial nephritis may produce rising creatinine, low complement, characteristic cortical lesions on imaging, or protein and blood in urine.
- Retroperitoneum: Fibrosis can encase the aorta or ureters, causing hydronephrosis and silent loss of kidney function.
- Aorta and arteries: Periaortitis, periarteritis, or inflammatory aneurysmal disease may occur.
- Lungs and chest: Nodules, airway disease, pleural thickening, lymphadenopathy, or interstitial changes can mimic infection or cancer.
- Meninges and pituitary: Hypertrophic pachymeningitis or hypophysitis can cause headache, cranial nerve symptoms, or hormone deficiencies.
- Thyroid, prostate, skin, lymph nodes, and other sites: Less specific manifestations require careful differential diagnosis.
The organ pattern is often more informative than one biomarker. For example, simultaneous autoimmune pancreatitis, salivary-gland enlargement, and retroperitoneal fibrosis strongly suggests a unifying systemic disease. An isolated enlarged lymph node with a mild serum elevation is much less specific.
Tests are chosen by organ. They may include liver enzymes and bilirubin, creatinine and eGFR, urinalysis, complement C3 and C4, pancreatic imaging, CT or MRI of involved regions, PET/CT in selected cases, pulmonary function tests, and hormone studies. An IgG4 blood test is only one component of that organ-directed workup.
How Clinicians Build the Diagnosis
A reliable diagnosis uses an evidence ladder rather than a single cutoff.
First, identify a compatible clinical and radiologic lesion. Diffuse or localized enlargement, a mass, wall thickening, or characteristic fibrosis in one or more organs creates the reason to suspect IgG4-related disease. The imaging pattern should be reviewed by someone familiar with both IgG4-related disease and its mimics.
Second, assess supportive laboratory findings. Serum IgG4 may be high. Total IgG, IgE, and eosinophils may also rise. Complement can be low in kidney involvement. CRP may be normal or only mildly elevated, so a normal CRP result does not indicate that an enlarging lesion is harmless.
Third, exclude competing diagnoses. Cancer, lymphoma, infection, ANCA-associated vasculitis, sarcoidosis, Sjögren disease, primary sclerosing cholangitis, idiopathic retroperitoneal fibrosis, and multicentric Castleman disease can overlap clinically or histologically. Some of these require very different and urgent treatment.
Fourth, obtain tissue when feasible. The preferred biopsy site is an involved organ that can be sampled safely and is likely to show diagnostic architecture. Core or surgical tissue is often more useful than fine-needle aspiration because the pathologist needs to evaluate fibrosis and vessel changes, not merely count cells.
Characteristic pathology includes a dense lymphoplasmacytic infiltrate, storiform—or cartwheel-like—fibrosis, and obliterative phlebitis. Eosinophils may be present. Immunostaining shows increased IgG4-positive plasma cells and an elevated IgG4-to-IgG plasma-cell ratio, but numeric cutoffs differ by organ. Counting IgG4-positive cells without the appropriate tissue pattern can misclassify other inflammatory diseases.
Diagnostic criteria and classification criteria serve related but different purposes. Comprehensive diagnostic criteria help clinicians describe definite, probable, or possible disease using organ lesions, serum findings, and pathology. The 2019 ACR/EULAR classification system was designed to create highly specific research cohorts after exclusion criteria are applied. A patient can require treatment despite not meeting research classification, and another person can meet several supportive features while still having a better alternative diagnosis. The criteria should organize judgment, not replace it.
Biopsy is not always possible. Pancreatic and vascular lesions may be difficult to sample, and some patients have a classic multi-organ pattern with strong serologic and imaging support. In those cases, specialists may apply organ-specific criteria and multidisciplinary judgment. A response to corticosteroids can support the overall picture but should not be used as a diagnostic shortcut because lymphoma and other disorders may also improve temporarily.
Using IgG4 to Monitor Disease
Serum IgG4 often falls with effective treatment and can be useful as one monitoring marker, particularly in a patient whose concentration was clearly elevated at baseline. It is not a complete activity score. Some patients enter clinical remission while the value remains above normal; others relapse with little or no rise.
Monitoring should match the organs at risk. A patient with kidney disease needs creatinine, eGFR, urinalysis, protein measurement, and sometimes complement. Biliary disease requires liver tests and imaging. Retroperitoneal fibrosis requires assessment of ureteral obstruction and hydronephrosis. Orbital disease may require formal visual and motility evaluation. Aortic disease requires vascular imaging.
Trend interpretation is more useful than a single number, but several cautions apply:
- Compare values from the same laboratory or account for method changes.
- Confirm units before judging the size of a change.
- Interpret the trend beside symptoms, imaging, and organ-function tests.
- Do not increase treatment solely because a mildly elevated number persists.
- Do not assume remission solely because serum IgG4 normalized.
Other blood findings may move with activity, including total IgG, IgE, eosinophils, and complement. None is universally reliable. Plasmablast assays and other newer biomarkers are being studied, but they are not routine in most clinical laboratories.
Treatment commonly begins with glucocorticoids when active disease threatens an organ. Rituximab or other steroid-sparing therapy may be used for relapse, high-risk disease, or difficulty tapering steroids. Fibrotic damage may not reverse even when inflammation is controlled, which is why early recognition of obstruction or organ dysfunction is important.
Next Steps and Urgent Warning Signs
For a high IgG4 result, the first question is why the test was ordered. If there is no compatible symptom, examination finding, or imaging abnormality, repeating the value and reviewing other causes may be more appropriate than launching extensive scans. If a suspicious lesion is already present, evaluation should proceed through the relevant specialist—often rheumatology, gastroenterology, nephrology, pulmonology, ophthalmology, urology, or vascular medicine.
Useful next steps may include review of the exact value and upper limit of normal, total immunoglobulins, serum protein electrophoresis, blood count with eosinophils, kidney and liver tests, complement, urinalysis, and targeted imaging. The team should identify the safest high-yield biopsy site rather than automatically sample the easiest enlarged lymph node, which may show nonspecific changes.
Prompt assessment is needed for jaundice, dark urine, pale stool, severe abdominal or back pain, reduced urine output, new leg or facial swelling, or rapidly rising creatinine. Visual loss, severe eye pain, double vision with orbital swelling, new weakness, cranial nerve symptoms, or severe headache may signal orbital, meningeal, or pituitary involvement.
Chest pain, fainting, sudden severe back or abdominal pain, coughing blood, and marked shortness of breath require emergency evaluation because vascular or pulmonary complications and their mimics can be life-threatening. Fever, drenching sweats, rapid weight loss, or a rapidly enlarging mass should prompt careful investigation for infection or malignancy rather than automatic attribution to IgG4-related disease.
The safest interpretation is proportional: a borderline result is a weak clue, a large elevation in a classic multi-organ pattern is a strong clue, and neither replaces tissue and organ assessment when the diagnosis remains uncertain.
References
- Current and Future Advances in Practice: IgG4-Related Disease. 2024. Peer-reviewed clinical review.
- Multiorgan Involvement and Circulating IgG1 Predict Disease Activity, Damage and Relapse in IgG4-Related Disease. 2024. Peer-reviewed cohort study.
- Diagnostic Utility of Serum IgG4 Level in IgG4-Related Diseases: A Comprehensive Systematic Review and Meta-analysis. 2023. Systematic review and meta-analysis.
- Differential Sensitivity of the 2020 Revised Comprehensive Diagnostic Criteria and the 2019 ACR/EULAR Classification Criteria Across IgG4-Related Disease Phenotypes. 2023. Peer-reviewed diagnostic study.
- The 2020 Revised Comprehensive Diagnostic (RCD) Criteria for IgG4-RD. 2021. Consensus diagnostic criteria.
- IgG4-Related Autoimmune Pancreatitis and Sclerosing Cholangitis: A Comprehensive Review. 2024. Peer-reviewed review.
Disclaimer
This article is educational and does not replace medical evaluation. IgG4 results must be interpreted with the laboratory range, symptoms, imaging, organ-function tests, pathology, and competing diagnoses. Seek urgent care for jaundice with illness, reduced urine, sudden visual or neurologic symptoms, chest pain, severe breathlessness, fainting, or sudden severe abdominal or back pain.
